Brightseed has introduced Rapid Profiling and expanded its microbiome discovery programs for partner companies

Photo © Shutterstock.com/PabloLagarto

Brightseed (San Francisco, CA) has introduced Rapid Profiling and expanded microbiome capabilities to help its partners unlock novel health insights for product development and accelerated commercialization timelines. The company’s microbiome discovery programs, for example, include the identification of microbially-derived bioactives and their associated health benefits when fermented ingredients or other prebiotic materials interact with gut bacteria. To this end, Brightseed is working with CJ Foods to collect and analyze fermented sources from around the world.

“Our microbiome programs, which also include synbiotic product development, are tailored for companies who are deeply vested in bringing novel and clinically validated products into their food and consumer health portfolios,” said David Brown, vice president of Business Development at Brightseed, in a press release. “The global market size for probiotics is valued at $58 billion, and synbiotics provide more robust benefits to consumers than probiotics alone. Forager allows us to predict bioactives resulting from the interaction between bacterial strains and natural ingredients, which is an exciting application of AI in microbiome research and innovation.”

Brightseed also says it can co-develop novel bioactive ingredients in specific health areas of interest as well as leverage its Forager AI to investigate the full health potential of a client’s existing portfolio. The company states that the addition of Rapid Profiling to its partner programs allows Brightseed to deliver actionable insights into phytochemical and bioactive compositions of their ingredients or supply chain in as little as six to eight weeks. This provides partner companies an accelerated roadmap for clinical validation and commercialization, Brightseed explains.

“Brightseed’s innovation programs and our dedicated pipeline of bioactive ingredients are designed to empower the nutrition industry with differentiated and efficacious solutions that target key consumer health areas including gut health, metabolic health, and cognition,” said Brown. “With Rapid Profiling and our expanded microbiome capacity, we are delivering innovative health products at a fraction of the time and cost of traditional discovery and development approaches. This enables our partners to expand into new health areas and diversify the ways in which they can investigate bioactives in their existing products, supply chains, side streams and waste streams.”

According to Brightseed, its Forager AI has mapped over 7 million compounds from plants, fungi, and bacterial strains across 23 human health areas. The company will be presenting its AI benchmarks, capabilities, and research at the IPA World Congress + Probiota Americas 2024 conference in Salt Lake City, UT on Wednesday, June 12.